Join Crux Biolabs in Switzerland for a Presentation on “Advantage Australia” and Learn Why International Biotechs Turn to Australia to Accelerate Their Clinical Research

By Stefan Cross, Senior Scientist

This May, Crux Biolabs is proud to be part of an important conversation—one that may shape the trajectory of early-phase clinical development for biotech and small pharma companies in Switzerland and beyond. And we are inviting you to join us.

As part of a joint delegation presenting at Swiss Biotech Day in Basel (May 5–6) and a special satellite event in Zurich (May 8), Crux Biolabs will join three other Australian-based organisations—Accelagen, RDI Partners, and Veritus Research—to present a compelling case for why more companies should consider Australia for early-phase clinical research.

The Zurich event, titled “Advantage Australia”, is designed specifically for companies with preclinical assets that are preparing for first-in-human studies. These pivotal moments are often expensive, high-stakes decisions—and we believe Australia offers a strategic edge that deserves your attention.

Why Australia? Timing, Cost, and Quality

While many European companies instinctively look toward the U.S. or other parts of Europe when advancing clinical programs, Australia presents a unique trifecta of advantages: speed, affordability, and scientific excellence.

Studies in Australia can initiate in as little as six weeks—dramatically faster than the 4–6 month IND timelines common in the U.S. Coupled with up to 43.5% R&D tax incentive, early-phase trials in Australia are often more cost-effective without sacrificing quality. Australian trial data is globally accepted and compatible with EMA and FDA submissions, allowing for smooth progression into global development plans.

A Full-Service, End-to-End Clinical Ecosystem

The Zurich panel event will showcase how Australian organisations seamlessly collaborate to provide a turnkey clinical trial experience. Each of the four presenting companies represents a critical piece of the ecosystem:

• Accelagen serves as the clinical research organisation (CRO), offering full program oversight, from site selection to recruitment to study completion.
• Crux Biolabs provides comprehensive bioanalytical services, ensuring reliable, high-quality data collection and interpretation.
• Veritus Research offers a 42-bed Phase I clinical facility and access to robust healthy volunteer and patient recruitment networks.
• RDI Partners advises on strategic access to Australia’s R&D tax incentives and financial planning for international sponsors.

Together, this panel represents a microcosm of Australia’s broader clinical trial infrastructure, demonstrating just how simple, efficient, and effective running a trial in Australia can be.

What to Expect from the Zurich Event

The panel—designed for biotech and pharma companies on the cusp of human trials—will take attendees through the entire Australian clinical trial experience. From regulatory nuances to operational workflows and financial incentives, the session will answer the key question: Why should I consider Australia for my first-in-human program?

This interactive event is not a sales pitch. It’s an information-sharing session where industry professionals can ask candid questions, explore specific concerns, and walk away with a clear sense of what working in Australia truly looks like. The session will wrap with informal networking to continue conversations in a more relaxed setting.

Why You Should Attend

If you’re evaluating where to take your preclinical asset next, this event could save you time, money, and headaches. Australia’s proven track record, streamlined startup timelines, and globally accepted data make it an option worth serious consideration—especially in today’s ever-shifting regulatory and geopolitical climate.

As Stefan Cross, CEO of Crux Biolabs, put it:

“Every stage of clinical development is a major investment. Taking one hour to explore a faster, more cost-effective alternative with real-world results—it’s not just smart, it’s essential.”

---

Join Us in Zurich – May 8

Whether you’re ready to make a move or just beginning to explore your options, Advantage Australia is the event to attend. Let us show you why Australia is more than just a destination—it’s an advantage.

For more information or to register, click here.

Contact us today to learn more about how we can help accelerate your research.